Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454

NCT04328740 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT04328740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04328740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2020
Completion date
April 25, 2025
Enrollment
31 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, anal cancer